S. 4355, Transparency and Accountability Measure. Quorum's AI analysis reads it as a net benefit — and names who gains.
S. 4355 · Net good
What it does
This bill requires the Department of Health and Human Services to publicly release all documents, contracts, and communications related to drug pricing agreements struck between the federal government and pharmaceutical manufacturers since January 20, 2025—including specific deals with 16 named companies. The bill mandates disclosure within 30 days, with limited exceptions for proprietary pricing data and legally protected information, and requires Congress and independent auditors to analyze the economic and budgetary effects of these agreements on drug prices and federal programs.
The analysis did not isolate a single beneficiary class.
The trade-off
Disclosure of proprietary pricing data (even if redacted) may reveal negotiating strategies and leverage points that manufacturers could use in future negotiations, potentially weakening the government's hand in subsequent deals.
Transparency scores 85%, with a medium warning level and no provisions unrelated to the bill's subject.
Who is behind it
Filed by Ron Wyden. Cosponsored by Ben Luján, Bernie Sanders, Catherine Cortez Masto and Chris Van Hollen.